Boston Scientific Cuts Sales and Profit Forecasts After Cyberattack

Boston Scientific has revised its sales and profit expectations downward following a cyberattack. The company stated that the attack adversely affected some of its operations and supply chain, leading to delays in product shipments. This development caused a notable decline in the stock price and heightened investor concerns about the company's short-term financial performance. The cyberattack reportedly targeted the company's information technology systems, disrupting production and distribution processes. Boston Scientific said it took immediate measures to contain the impact of the attack and that systems are gradually returning to normal. However, the disruption is expected to result in third-quarter sales revenue below forecasts. The company revised its previously announced sales and adjusted profit guidance for 2024, estimating the financial impact of the cyberattack at approximately $300 million. This revision once again highlights the effect of cybersecurity risks on financial results in the medical device sector. Boston Scientific's management emphasized that they are focusing on improving operations while prioritizing customer and patient safety following the attack. Analysts note that such cyber incidents can cause long-term damage to companies' reputations and operational resilience. Boston Scientific's shares lost value following the news, with a significant decline in market capitalization. The company's future investments in cybersecurity infrastructure and the measures it takes will play a critical role in restoring investor confidence. This is not investment advice.